Gland Pharma Limited (BOM:543245)

Market Cap	276.56B
Revenue (ttm)	58.01B
Net Income (ttm)	7.90B
Shares Out	n/a
EPS (ttm)	47.98
PE Ratio	34.99
Forward PE	25.67
Dividend	18.00 (1.06%)
Ex-Dividend Date	Aug 14, 2025

Volume	3,332
Average Volume	5,218
Open	1,686.05
Previous Close	1,692.85
Day's Range	1,675.00 - 1,719.90
52-Week Range	1,200.00 - 2,130.00
Beta	n/a
RSI	30.61
Earnings Date	Jan 28, 2026

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,351
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2024, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.